Silymarin improved diet-induced liver damage and insulin resistance by decreasing inflammation in mice

References

• Abdel-Moneim AM, Al-Kahtani MA, El-Kersh MA, Al-Omair MA. 2015. Free radical-scavenging, anti-inflammatory/anti-fibrotic and hepatoprotective actions of taurine and silymarin against CCl4 induced rat liver damage. PLoS One. 10:e0144509.
   PubMed Web of Science ®Google Scholar
• Bugianesi E, McCullough AJ, Marchesini G. 2005. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 42:987–1000.
   PubMed Web of Science ®Google Scholar
• Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, Gueripel X, Ellingsgaard H, Schneider MK, Biollaz G, et al. 2007. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes. 56:2356–2370.
   PubMed Web of Science ®Google Scholar
• Forouhi NG, Wareham NJ. 2014. Epidemiology of diabetes. Medicine (Abingdon). 42:698–702.
   PubMedGoogle Scholar
• Gillessen A, Herrmann WA, Kemper M, Morath H, Mann K. 2014. Effect of silymarin on liver health and quality of life. Results of a non-interventional study. MMW Fortschr Med. 156:120–126.
   PubMedGoogle Scholar
• Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. 2014. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 103:137–149.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 259:87–91.
   PubMed Web of Science ®Google Scholar
• Jourdan T, Godlewski G, Cinar R, Bertola A, Szanda G, Liu J, Tam J, Han T, Mukhopadhyay B, Skarulis MC, et al. 2013. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med. 19:1132–1140.
   PubMed Web of Science ®Google Scholar
• Kahn BB, Flier JS. 2000. Obesity and insulin resistance. J Clin Invest. 106:473–481.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Lee MY, Jeon YJ. 2015. Silymarin inhibits morphological changes in LPS-stimulated macrophages by blocking NF-kappaB pathway. Korean J Physiol Pharmacol. 19:211–218.
   PubMed Web of Science ®Google Scholar
• Lovelace ES, Wagoner J, MacDonald J, Bammler T, Bruckner J, Brownell J, Beyer RP, Zink EM, Kim YM, Kyle JE, et al. 2015. Silymarin suppresses cellular inflammation by inducing reparative stress signaling. J Nat Prod. 78:1990–2000.
   PubMed Web of Science ®Google Scholar
• Luangchosiri C, Thakkinstian A, Chitphuk S, Stitchantrakul W, Petraksa S, Sobhonslidsuk A. 2015. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complement Altern Med. 15:334.
   PubMed Web of Science ®Google Scholar
• Matthaei S, Stumvoll M, Kellerer M, Haring HU. 2000. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev. 21:585–618.
   PubMed Web of Science ®Google Scholar
• Minihane AM, Vinoy S, Russell WR, Baka A, Roche HM, Tuohy KM, Teeling JL, Blaak EE, Fenech M, Vauzour D, et al. 2015. Low-grade inflammation, diet composition and health: current research evidence and its translation. Br J Nutr. 114:999–1012.
   PubMed Web of Science ®Google Scholar
• Piya MK, McTernan PG, Kumar S. 2013. Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin. J Endocrinol. 216:T1–T15.
   Web of Science ®Google Scholar
• Prakash P, Singh V, Jain M, Rana M, Khanna V, Barthwal MK, Dikshit M. 2014. Silymarin ameliorates fructose induced insulin resistance syndrome by reducing de novo hepatic lipogenesis in the rat. Eur J Pharmacol. 727:15–28.
   PubMed Web of Science ®Google Scholar
• Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, Dunaif A, White MF. 2001. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest. 107:181–189.
   PubMed Web of Science ®Google Scholar
• Saltiel AR. 2000. Series introduction: the molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular diseases. J Clin Invest. 106:163–164.
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Lee J, Goldfine AB. 2006. Inflammation and insulin resistance. J Clin Invest. 116:1793–1801.
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Herrero L, Naaz A. 2007. Obesity, inflammation, and insulin resistance. Gastroenterology. 132:2169–2180.
   PubMed Web of Science ®Google Scholar
• Tateya S, Kim F, Tamori Y. 2013. Recent advances in obesity-induced inflammation and insulin resistance. Front Endocrinol (Lausanne). 4:93.
   PubMedGoogle Scholar
• Toyoda-Hokaiwado N, Yasui Y, Muramatsu M, Masumura K, Takamune M, Yamada M, Ohta T, Tanaka T, Nohmi T. 2011. Chemopreventive effects of silymarin against 1,2-dimethylhydrazine plus dextran sodium sulfate-induced inflammation-associated carcinogenicity and genotoxicity in the colon of gpt delta rats. Carcinogenesis. 32:1512–1517.
   PubMed Web of Science ®Google Scholar
• Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. 2011. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 17:179–188.
   PubMed Web of Science ®Google Scholar
• Wen H, Ting JP, O'Neill LA. 2012. A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation? Nat Immunol. 13:352–357.
   PubMed Web of Science ®Google Scholar
• Wu JP, Tsai CC, Yeh YL, Lin YM, Lin CC, Day CH, Shen CY, Padma VV, Pan LF, Huang CY. 2015. Silymarin accelerates liver regeneration after partial hepatectomy. Evid Based Complement Alternat Med. 2015:603529.
   PubMed Web of Science ®Google Scholar
• Wu YF, Fu SL, Kao CH, Yang CW, Lin CH, Hsu MT, Tsai TF. 2008. Chemopreventive effect of silymarin on liver pathology in HBV X protein transgenic mice. Cancer Res. 68:2033–2042.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hai J, Cao M, Pei S, Wang J, Zhang Q. 2013. Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1/PI3K/Akt pathway. Int Immunopharmacol. 17:714–720.
   PubMed Web of Science ®Google Scholar